UroGen Pharma (URGN): Q3 revenue $89.0M; nine-month revenue $212.4M
Q3 2026 product revenue $89.0M, nine-month $212.4M; cost of revenue rose to $7.5M from $3.3M on higher Zusduri sales volumes.
What this filing says
UroGen's latest quarterly report shows $89.0 million of product revenue for the three months ended September 30, 2026, and $212.4 million for the nine months. Cost of revenue rose as sales volumes grew, and the company expects inventory it previously expensed as R&D to keep lowering cost of revenue into early 2027. The filing also restates the 2024 share offering that raised gross proceeds of $107.5 million.
Key figures
- Three-month revenue
- $89.0 million
- Nine-month revenue
- $212.4 million
- Three-month cost of revenue
- $7.5 million
- Nine-month cost of revenue
- $18.2 million
- 2024 offering gross proceeds
- $107.5 million
- Ordinary shares outstanding
- 49,047,823 shares
Positive for shareholders
- Product revenue reached $89.0 million in the quarter and $212.4 million over nine months.
- Cost of revenue is expected to benefit from depleting Zusduri inventory previously expensed as R&D, into early 2027.
Negative for shareholders
- Cost of revenue rose to $7.5 million for the quarter from $3.3 million a year earlier, as sales volumes increased.
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- Pre-funded warrant:
- A warrant sold at nearly the full share price that lets the holder buy shares for a nominal amount later, used to let investors avoid owning shares immediately.
- Zusduri:
- UroGen's approved product, which the filing says received FDA approval before its inventory costs were recognized as revenue-related costs.
FAQ
How much revenue did UroGen Pharma report for the third quarter of 2026?
UroGen recognized $89.0 million of revenue from product sales in the three months ended September 30, 2026.
Why did UroGen's cost of revenue increase?
The filing says cost of revenue rose mainly because sales volumes increased, partly offset by inventory costs that were previously booked as research and development expenses before FDA approval of Zusduri.
Historical context for URGN
Across the 27 sessions after earlier URGN headlines, the stock closed higher 13 times and lower 14 times, with a median move of 2.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | URGN | SPY |
|---|---|---|---|
| Nov 4, 2026 | UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights | -16.5% | +1.7% |
| Nov 3, 2026 | UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference | +0.1% | +0.3% |
| Nov 2, 2026 | UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer | +5.0% | -0.5% |
| Oct 28, 2026 | UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancerand 1 other headline that session | -0.5% | +0.3% |
| Oct 19, 2026 | UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC | -1.2% | +0.4% |
| Sep 4, 2026 | UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -1.8% | -0.4% |
Keep researching URGN
- URGN financial statementsRevenue, profit, cash flow and balance sheet from UroGen Pharma Ltd.'s SEC filings.
- What is Form 10-Q?The quarterly report US public companies file with the SEC for each of the first three fiscal quarters, with unaudited financial statements and MD&A.
- Form 10-K vs 10-QThe difference between a 10-K and a 10-Q: what each report contains, filing deadlines by company size, audited vs reviewed financials, and which sections to read first.
- URGN insider tradesEvery buy and sale reported by UroGen Pharma Ltd. officers, directors and large holders.
- URGN earnings historyPast UroGen Pharma Ltd. earnings releases, newest first.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2017
Follow URGN and get a push notification the moment its next story breaks.